• About us
• Contact

Advertisement

Organisation › Details

Mirus Bio LLC

Mirus Bio pioneered scientific breakthroughs in non-viral gene delivery and continues to produce industry-leading transfection reagents. As we expand our expertise in nucleic acid delivery, we give life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing and genome editing. *

 

	Start	2008-07-22 splitoff (date ca.)
	Group	Merck (DE) (Group)
	Industry	transfection reagents
	Person	Gordon, Dale (Mirus Bio 202405 CEO)
	Region	Madison, WI
	Country	United States (USA)
	Street	5602 Research Park Blvd. Suite 210
	City	53719 Madison, WI
	Tel	+1-608-441-2852
		Address record changed: 2024-11-30
Basic data	Employees	n. a.
		* Document for »About Section«: Gamma Biosciences. (5/18/21). "Press Release: Gamma Biosciences Acquires Controlling Stake in Mirus Bio to Expand Reach in Gene Therapy and Next Generation Vaccines". Menlo Park, CA & Madison, WI.
		Record changed: 2024-11-30

Advertisement

More documents for Merck (DE) (Group)

• [1] Merck KGaA. (12/17/24). "Press Release: Merck to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio". Darmstadt....
• [2] Max Planck Innovation GmbH. (12/17/24). "Press Release: Christoph Hüls Becomes Managing Director of Max Planck Innovation GmbH, Succeeding Jörn Erselius, Who Is Retiring after more than 30 Years of Service"....
• [3] Single Use Support GmbH. (12/16/24). "Press Release: Darren Verlenden New CEO of Single Use Support". Kufstein....
• [4] Enara Bio Ltd.. (10/3/24). "Press Release: Enara Bio Raises $32.5 Million Series B Financing to Advance First-in-Class Pipeline of TCR-based Immunotherapies Targeting Novel Dark Antigens". Oxford....
• [5] Merck KGaA. (6/24/24). "Press Release: Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck Cancer [ Not intended for UK-, US- or Canada-based media ]". Darmstadt....
• [6] Merck KGaA. (5/29/24). "Press Release: Merck Signs MoU with KAIST to Advance Scientific Collaboration". Darmstadt....
• [7] Merck KGaA. (5/22/24). "Press Release: Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 Million". Darmstadt....
• [8] Merck KGaA. (4/25/24). "Press Release: Merck Invests More Than € 300 Million in New Life Science Research Center in Germany". Darmstadt....
• [9] Outrun Therapeutics Ltd.. (4/18/24). "Press Release: Outrun Therapeutics Launches with a $10m Seed Financing from M Ventures and MP Healthcare Venture Management to Develop a Protein Stabilisation Pipeline". Dundee....
• [10] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.